Patents by Inventor M. Reza Mirbolooki

M. Reza Mirbolooki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
    Patent number: 9878006
    Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: January 30, 2018
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, KINETA ONE, LLC
    Inventors: K. George Chandy, Sanjeev Kumar Upadhayay, Ping H. Wang, Paolo Sassone-Corsi, Kristin Lynn Eckel-Mahan, Shawn Iadonato, Jogesh Mukherjee, M. Reza Mirbolooki
  • Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels
    Publication number: 20170095530
    Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.
    Type: Application
    Filed: February 22, 2016
    Publication date: April 6, 2017
    Inventors: K. George Chandy, Sanjeev Kumar Upadhayay, Ping H. Wang, Paolo Sassone-Corsi, Kristin Lynn Eckel-Mahan, Shawn Iadonato, Jogesh Mukherjee, M. Reza Mirbolooki
  • Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels
    Publication number: 20150072940
    Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.
    Type: Application
    Filed: October 2, 2012
    Publication date: March 12, 2015
    Inventors: K. George Chandy, Sanjeev Kumar Upadhayay, Ping H. Wang, Paolo Sassone-Corsi, Kristin Lynn Eckel-Mahan, Shawn Iadonato, Jogesh Mukherjee, M. Reza Mirbolooki